Eli Lilly and Company (LILY34.SA)
| Previous Close | 145.89 |
| Open | 144.26 |
| Bid | 144.50 x 0 |
| Ask | 144.62 x 0 |
| Day's Range | 143.51 - 146.15 |
| 52 Week Range | 69.46 - 146.15 |
| Volume | |
| Avg. Volume | 13,854 |
| Market Cap | 4.12T |
| Beta (5Y Monthly) | 0.37 |
| PE Ratio (TTM) | 122.46 |
| EPS (TTM) | 1.18 |
| Earnings Date | Aug 08, 2024 |
| Forward Dividend & Yield | 0.62 (0.42%) |
| Ex-Dividend Date | May 15, 2024 |
| 1y Target Est | N/A |
Investor's Business DailyS&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Eli Lilly, Novo Nordisk, Vertex Pharmaceuticals, Intuitive Surgical and Universal Health are all trading in or near buy zones. Medical stocks are often viewed as defensive growth stocks, because their growth is insulated from economic swings due to the government or insurance covering most of the costs. Eli Lilly is in a buy zone while weight-loss drug rival and fellow IBD Leaderboard member Novo Nordisk is setting up.
PR NewswireUpdated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced solid tumors and in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC). Olomorasib is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein. These data will be shared in o
ZacksTop Research Reports for Eli Lilly, T-Mobile & BHP
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), T-Mobile US, Inc. (TMUS) and BHP Group Limited (BHP).
